Annovis Bio, Inc. ANVS
Annovis Bio, Inc. (NYSE: ANVS) is a CNS/neurology/psychiatry drug developer. Its lead program, Buntanetap, is in Phase 3 for Early Alzheimer's disease. Its next catalyst on record is Buntanetap: AD OLE start (October 2026).
Upcoming catalysts
- October 2026Buntanetap — AD OLE start
Next further out: Buntanetap — Pivotal Phase 3 AD readout (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Buntanetap | Early Alzheimer's disease (NCT06709014) | small molecule | Phase 3 |
| Buntanetap | Parkinson's disease open-label extension (NCT07284784) | small molecule | Phase 3 |
| Buntanetap | Alzheimer's open-label extension | small molecule | Phase 3 |
| Buntanetap | Parkinson's disease dementia | small molecule | Phase 2 |
Recent results and decisions
- Jul 7, 2026completed enrollment Pivotal Phase 3 AD trial fully enrolled with 850 patients, above the 760 target.
today announced full enrollment of its pivotal Phase 3 trial (NCT06709014) evaluating buntanetap in patients with early AD.
Filing - Mar 16, 2026positive DSMB gave a positive safety recommendation at 6 months (February 2026), allowing the pivotal Phase 3 AD trial to continue unmodified.
In February 2026, Annovis received a positive recommendation from the Data and Safety Monitoring Board (DSMB) regarding buntanetap’s safety at 6 months, supporting the continuation of the trial without modifications.
Filing - Mar 16, 2026n/a After a January 2026 FDA meeting, Annovis received a positive recommendation to proceed with a new PD dementia study; design and endpoints under discussion.
The Company received a positive recommendation to proceed and is currently in discussions with the FDA to determine the trial design and endpoints for its execution.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.